<DOC>
	<DOC>NCT00984867</DOC>
	<brief_summary>This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.</brief_summary>
	<brief_title>Dapagliflozin DPPIV Inhibitor add-on Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients with type 2 diabetes Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these Patients will be screened by a blood test and only those who need additional therapy can be enrolled Patients with type 1 diabetes Patients with very poorly controlled diabetes Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Dapagliflozin DPP IV inhibitor add on study</keyword>
	<keyword>Inadequate control</keyword>
</DOC>